Insulin Analogues in the Treatment of Diabetes in Pregnancy

Obstetrics and Gynecology Clinics of North America

Volumn 34, Issue 2, 2007, Pages 275-291

  Singh, Charanpal ^a   Jovanovic, Lois ^a  

^a SANSUM DIABETES RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; INSULIN RECEPTOR; ISOPHANE INSULIN; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

ANTIBODY PRODUCTION; CLINICAL TRIAL; DIABETIC RETINOPATHY; DISEASE SEVERITY; DRUG CHOICE; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG USE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; MEDICAL DECISION MAKING; NONHUMAN; PLACENTAL TRANSFER; POSTPRANDIAL STATE; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR AFFINITY; REVIEW; RISK FACTOR;

DIABETES, GESTATIONAL; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; PREGNANCY; PREGNANCY IN DIABETICS; RECEPTOR, IGF TYPE 1;

EID: 34250024035     PISSN: 08898545     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ogc.2007.03.003     Document Type: Review

References (94)

1. Pedersen J. Course of diabetes during pregnancy. Acta Endocrinol (Copenh) 9 (1952) 342-347
2. Mills J.L., Knopp R.H., Simpson J.L., et al. Lack of relation of increased malformation rates in infants of diabetic mothers to glycemic control during organogenesis. N Engl J Med 318 (1988) 671-676
3. Mills J.L., Simpson J.L., Driscoll S.G., et al. Incidence of spontaneous abortion among normal women and insulin-dependent diabetic women whose pregnancies were identified within 21 days of conception. N Engl J Med 319 (1988) 1617-1623
4. Mills J.L., Fishl A.R., Knopp R.H., et al. Malformations in infants of diabetic mothers: problems in study design. Prev Med 12 (1983) 274-286
5. Jovanovic L., Peterson C.M., Saxena B.B., et al. Feasibility of maintaining normal glucose profiles in insulin-dependent pregnant diabetic women. Am J Med 68 (1980) 105-112
6. DeVeciana M., Major C.A., Morgan M.A., et al. Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy. N Engl J Med 333 (1995) 1237-1241
7. Combs C.A., Gunderson E., Kitzmiller J.L., et al. Relationship of fetal macrosomia to maternal postprandial glucose control during pregnancy. Diabetes Care 15 (1992) 1251-1257
8. Jovanovic L., Peterson C.M., Reed G.F., et al. Maternal postprandial glucose levels and infant birth weight: the diabetes in early pregnancy study. Am J Obstet Gynecol 164 (1991) 103-111
9. Jovanovic L. What is so bad about a big baby?. [editorial]. Diabetes Care 24 (2001) 1317-1318
10. Challier J.C., Haugel S., and Desmaizieres V. Effects of insulin on glucose uptake and metabolism in the human placenta. J Clin Endocrinol Metab 62 (1986) 803-807
11. Boskovic R., Feig D.S., Derewlany L., et al. Transfer of insulin lispro across the human placenta: in vitro perfusion studies. Diabetes Care 26 (2003) 1390-1394
12. Menon R.K., Cohen R.M., Sperling M.A., et al. Transplacental passage of insulin in pregnant women with insulin-dependent diabetes mellitus. Its role in fetal macrosomia. N Engl J Med 323 (1990) 309-315
13. Jovanovic L., Kitzmiller J.L., and Peterson C.M. Randomized trial of human versus animal species insulin in diabetic pregnant women: improved glycemic control, not fewer antibodies to insulin, influences birth weight. Am J Obstet Gynecol 167 (1992) 1325-1330
14. Moses R.G., Lucas E.M., and Knights S. Gestational diabetes mellitus: at what time should the postprandial glucose level be monitored?. Aust N Z J Obstet Gynecol 39 (1999) 457-460
15. Anderson Jr. J.H., Brunelle R.L., Koivisto V.A., et al. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analogue treatment. Diabetes 46 (1997) 265-270
16. Fineberg S.E., Rathbun M.J., Hufferd S., et al. Immunologic aspects of human proinsulin therapy. Diabetes 37 (1988) 276-280
17. Fineberg N.S., Fineberg S.E., Anderson J.H., et al. Immunologic effects of insulin lispro Lys (B23), Pro (B29) human insulin in IDDM and NIDDM patients previously treated with insulin. Diabetes 45 (1996) 1750-1754
18. Setter S.M., Corbett C.F., Campbell R.K., et al. Insulin aspart: a new rapid-acting insulin analogue. Ann Pharmacother 34 (2000) 1423-1431
19. Calle-Pascual A.L., Bagazgoitia J., Calle J.R., et al. Use of insulin lispro in pregnancy. Diabetes Nutr Metab 13 (2003) 173-177
20. Jovanovic L., Ilic S., Pettitt D.J., et al. The metabolic and immunologic effects of insulin lispro in gestational diabetes. Diabetes Care 22 (1999) 1422-1426
21. Jovanovic L., Druzin M., and Peterson C.M. The effect of euglycemia on the outcome of pregnancy in insulin-dependent diabetics as compared to normal controls. Am J Med 7l (1981) 921-927
22. Jovanovic L., Mills J., Knopp R.H., et al., the National Institute of Child Health and Human Development-Diabetes in Early Pregnancy Study Group. Declining insulin requirement in the late first trimester of diabetic pregnancy. Diabetes Care 24 (2001) 1130-1136
23. Langer O., Yogev Y., Most O., et al. Gestational diabetes: the consequences of not treating. Am J Obstet Gynecol 192 (2002) 989-997
24. American Diabetes Association. Gestational diabetes mellitus (position statement). Diabetes Care 27 Suppl 1 (2004) S88-S90
25. Thompson D.M., Dansereau J., Creed M., et al. Tight glucose control results in normal perinatal outcome in 150 patients with gestational diabetes. Obstet Gynecol 83 (1994) 362-366
26. Langer O., and Mazze R. The relationship between large-for-gestational-age infants and glycemic control in women with gestational diabetes. Am J Obstet Gynecol 159 (1988) 1478-1483
27. Metzger B.E., and Coustan D.R. The Organizing Committee. Summary and recommendations of the Fourth International Workshop-Conference on Gestational Diabetes Mellitus. Diabetes Care 21 Suppl 2 (1998) B161-B167
28. In: Jovanovic L. (Ed). Medical management of pregnancy complicated by diabetes (2000), American Diabetes Association, Alexandria (VA)
29. Engelgau M., German R., Herman W., et al. The epidemiology of diabetes and pregnancy in the U.S. 1988. Diabetes Care 18 (1995) 1029-1033
30. Persson B., and Hanson U. Neonatal morbidities in gestational diabetes mellitus. Diabetes Care 21 Suppl 2 (1998) B79-B84
31. Hod M., Rabinerson D., and Peled Y. Gestational diabetes mellitus: is it a clinical entity?. Diabetes Rev 3 (1995) 603-613
32. Ogata E.S. Perinatal morbidity in offspring of diabetic mothers. Diabetes Rev 3 (1995) 652-657
33. Langer O. Is normoglycemia the correct threshold to prevent complications in the pregnant diabetic patient?. Diabetes Rev 4 (1995) 2-10
34. Platt M.J., Stanisstreet M., Casson I.F., et al. St Vincent declaration 10 years on: outcomes of diabetic pregnancies. Diabet Med 19 (2002) 216-220
35. Bolli G.B. Insulin treatment in type 1 diabetes. Endocr Pract 12 Suppl 1 (2006) 105-109
36. Ashwell S.G., Gebbie J., and Home P.D. Optimal timing of injection of once-daily insulin glargine in people with type 1 diabetes using insulin lispro at meal-times. Diabet Med 23 (2006) 46-52
37. Guerci B., and Sauvanet J.P. Subcutaneous insulin: pharmacokinetic variability and glycemic variability. Diabetes Metab 31 4 Pt 2 (2005) 4S7-4S24
38. Wilinska M.E., Chassin L.J., Schaller H.C., et al. Insulin kinetics in type-I diabetes: continuous and bolus delivery of rapid acting insulin. IEEE Trans Biomed Eng 52 1 (2005) 3-12
39. Hirsch I.B. Insulin analogues. N Engl J Med 352 2 (2005) 174-183
40. Heinemann L., Kapitza C., Starke A.A., et al. Time-action profile of the insulin analogue B28Asp. Diabet Med 13 (1996) 683-684
41. Home P.D., Lindholm A., Hylleberg B., et al. Improved glycemic control with insulin aspart: a multi-center randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group. Diabetes Care 21 (1998) 1904-1909
42. Home P.D., Barriocanal L., and Lindholm A. Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers. Eur J Clin Pharmacol 55 (1999) 199-203
43. Novo Nordisk Pharmaceutical Company. NovoLog Product Labeling Physicians' Desk Reference. 58th edition (2004), Thomson PDR, Montvale (NJ) p. 2355-2359
44. Rave K., Klein O., Frick A.D., et al. Advantage of premeal-injected insulin glulisine compared with regular human insulin in subjects with type 1 diabetes. Diabetes Care 29 8 (2006) 1812-1817
45. Hoogma R.P., and Schumicki D. Safety of insulin glulisine when given by continuous subcutaneous infusion using an external pump in patients with type 1 diabetes. Horm Metab Res 38 6 (2006) 429-433
46. Anderson J., Bastyr E., and Wishner K. Response to diamond and kormas. N Engl J Med 337 (1997) 1009-1012
47. Robinson D.M., and Wellington K. Insulin glulisine. Drugs 66 6 (2006) 861-869
48. Bhattacharyya A., Brown S., Huges S., et al. Insulin lispro and regular insulin in pregnancy. QJM 94 (2001) 255-260
49. Mecacci F., Carignani L., Cioni R., et al. Maternal metabolic control and perinatal outcome in women with gestational diabetes treated with regular or lispro insulin: comparison with non-diabetic pregnant women. Eur J Obstet Gynecol Reprod Biol 11 (2003) 19-24
50. Wyatt J.W., Frias J.L., Hoyme H.E., et al. Congenital anomaly rate in offspring of pre-gestational diabetic women treated with insulin lispro during pregnancy. Diabet Med 21 (2004) 2001-2007
51. Garg S.K., Frias J.P., Anil S., et al. Insulin lispro therapy in pregnancies complicated by diabetes type 1: glycemic control and maternal and fetal outcomes. Endocr Pract 9 (2003) 187-193
52. Pettitt D.J., Ospina P., Kolaczynski J., et al. Comparison of an insulin analogue, insulin aspart, and regular human insulin with no insulin in gestational diabetes mellitus. Diabetes Care 26 (2003) 183-186
53. Hod M. for the Novorapid Insulin Trial of the Safety and Efficacy of Insulin Aspart for the Treatment of Type 1 Diabetic Women during Pregnancy. Study design. Presented at the European Association for the Study of Diabetes, 2005.
54. Cypryk K., Sobczak M., Pertynska-Marczewska M., et al. Pregnancy complications and perinatal outcome in diabetic women treated with Humalog (insulin lispro) or regular human insulin during pregnancy. Med Sci Monit 10 2 (2004) PI29-PI32
55. Carr K.J., Idama T.O., Masson E.A., et al. A randomised controlled trial of insulin lispro given before or after meals in pregnant women with type 1 diabetes-the effect on glycaemic excursion. J Obstet Gynaecol 24 4 (2004) 382-386
56. Masson E.A., Patmore J.E., Brash P.D., et al. Pregnancy outcome in type 1 diabetes mellitus treated with insulin lispro (Humalog). Diabet Med 20 1 (2003) 46-50
57. Persson B., Swahn M.L., Hjertberg R., et al. Insulin lispro therapy in pregnancies complicated by type 1 diabetes mellitus. Diabetes Res Clin Pract 58 2 (2002) 115-121
58. Loukovaara S., Immonen I., Teramo K.A., et al. Progression of retinopathy during pregnancy in type 1 diabetic women treated with insulin lispro. Diabetes Care 26 4 (2003) 1193-1198
59. Rosenstock J., Dailey G., Massi-Benedetti M., et al. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 28 (2005) 950-955
60. Hofmann T., Horstmann G., and Stammberger I. Evaluation of the reproductive toxicity and embryotoxicity of insulin glargine (LANTUS) in rats and rabbits. Int J Toxicol 21 (2002) 181-189
61. Devlin J.T., Hothersall L., and Wilkis J.L. Use of insulin glargine during pregnancy in a type 1 diabetic woman. Diabetes Care 25 (2002) 1095-1096
62. Porcellati F., Rossetti P., Pampanelli S., et al. Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with type 1 diabetes mellitus given meal-time lispro insulin. Diabet Med 21 11 (2004) 1213-1220
63. Di Cianni G., Volpe L., Lencioni C., et al. Use of insulin glargine during the first weeks of pregnancy in five type 1 diabetic women. Diabetes Care 28 (2005) 982-983
64. Holstein A., Plaschke A., and Egberts E.H. Use of insulin glargine during embryogenesis in a pregnant woman with type 1 diabetes. Diabet Med 20 (2003) 779-780
65. Caronna S., Cioni F., Dall'Aglio E., et al. Pregnancy and the long-acting insulin analogue: a case study. Acta Biomed Ateneo Parmense 77 1 (2006) 24-26
66. Torlone E., Gennarini A., Ricci N.B., et al. Successful use of insulin glargine during entire pregnancy until delivery in six type 1 diabetic women. Eur J Obstet Gynecol Reprod Biol (2006 Jun 24) [Epub ahead of print]
67. Dolci M., Mori M., and Baccetti F. Use of glargine insulin before and during pregnancy in a woman with type 1 diabetes and Addison's disease. Diabetes Care 28 8 (2005) 2084-2085
68. Wooldrenrink J.M., van Loon A.J., Storms F., et al. Use of insulin glargine during pregnancy in seven type 1 diabetic women. Diabetes Care 28 (2005) 2394-2395
69. Graves D.E., White J.C., and Kirk J.K. The use of insulin glargine with gestational diabetes mellitus. Diabetes Care 29 2 (2006) 471-472
70. Hamilton-Wessler M., Ader M., Dea M., et al. Mechanism of protracted metabolic effects of fatty acid acylated insulin, NN304, in dogs: retention of NN304 by albumin. Diabetologia 42 (1999) 1254-1263
71. Kurtzhals P., Havelund S., Jonassen I., et al. Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochem J 312 Pt 3 (1995) 725-731
72. Whittingham J.L., Havelund S., and Jonassen I. Crystal structure of a prolonged-acting insulin with albumin-binding properties. Biochemistry 36 (1997) 2826-2831
73. Home P.D., Bartley P., Russell-Jones D., et al. Insulin detemir offers improved glycemic control compared with NPH insulin in people with Type 1 diabetes: a randomized clinical trial. Diabetes Care 27 (2004) 1081-1087
74. Hermansen K., Fontaine P., Kukolja K.K., et al. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with Type 1 diabetes. Diabetologia 47 (2004) 622-629
75. Druckmann R., and Rohr U.D. IGF-1 in gynaecology and obstetrics: update 2002. Maturitas 41 Suppl 1 (2002) S65-S83
76. Mandl M., J.Haas J., Bischof P., et al. Serum-dependent effects of IGF-I and insulin on proliferation and invasion of human first trimester trophoblast cell models. Histochem Cell Biol 117 (2002) 391-399
77. The Diabetes Control and Complications Trial Research Group. Effect of pregnancy on microvascular complications in the diabetes control and complications trial. Diabetes Care 23 (2000) 1084-1091
78. Lacroix M.C., Guibourdenche J., Frendo J.L., et al. Human placental growth hormone-a review. Placenta 23 Suppl A (2002) S87-S94
79. De Meyts P., and Whittaker J. Structural biology of insulin and IGF1 receptors: implications for drug design. Nat Rev Drug Discov 1 (2002) 769-783
80. Drejer K. The bioactivity of insulin analogues from in vitro receptor binding to in vivo glucose uptake. Diabetes Metab Rev 8 (1992) 259-285
81. Bahr M., Kolter T., Seipke G., et al. Growth promoting and metabolic activity of the human insulin analogue [GlyA21,ArgB31,ArgB32] insulin (HOE 901) in muscle cells. Eur J Pharmacol 320 (1997) 259-265
82. Kurtzhals P., Schaffer L., Sorensen A., et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogues designed for clinical use. Diabetes 49 (2000) 999-1005
83. Ciaraldi T.P., Carter L., Seipke G., et al. Effects of the long-acting insulin analogue insulin glargine on cultured human skeletal muscle cells: comparisons to insulin and IGF-I. J Clin Endocrinol Metab 86 (2001) 5838-5847
84. Sheth B.P. Does pregnancy accelerate the rate of progression of diabetic retinopathy?. Curr Diab Rep 2 (2002) 327-330
85. Henricsson M., Berntorp K., Berntorp E., et al. Progression of retinopathy after improved metabolic control in type 2 diabetic patients. Relation to IGF-1 and hemostatic variables. Diabetes Care 22 (1999) 1944-1949
86. Phelps R.L., Sakol P., Metzger B.E., et al. Changes in diabetic retinopathy during pregnancy. Correlations with regulation of hyperglycemia. Arch Ophthalmol 104 (1986) 1806-1810
87. Chew E.Y., Mills J.L., Metzger B.E., et al. Metabolic control and progression of retinopathy. The Diabetes in Early Pregnancy Study. National Institute of Child Health and Human Development Diabetes in Early Pregnancy Study. Diabetes Care 18 (1995) 631-637
88. DCCT Study Group and KROC Study Group. Diabetic retinopathy after two years of intensified insulin treatment. Follow-up of the Kroc Collaborative Study. The Kroc Collaborative Study Group. JAMA 260 (1988) 37-41
89. DCCT Study Group and KROC Study Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 329 (1993) 977-986
90. Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol 116 (1998) 874-886
91. Kondo T., Vicent D., Suzuma K., et al. Knockout of insulin and IGF-1 receptors on vascular endothelial cells protects against retinal neovascularization. J Clin Invest 111 (2003) 1835-1842
92. Kitzmiller J.L., Main E., Ward B., et al. Insulin lispro and the development of proliferative diabetic retinopathy during pregnancy. Diabetes Care 22 (1999) 874-876
93. Buchbinder A., Miodovnik M., McElvy S., et al. Is insulin lispro associated with the development or progression of diabetic retinopathy during pregnancy?. Am J Obstet Gynecol 183 (2000) 1162-1165
94. Jovanovic L. Retinopathy risk: what is responsible? Hormones, hyperglycemia, or Humalog? Response to Kitzmiller, et al. Diabetes Care 22 (1999) 846-848